Product Information
ISRADIPINE 2.5 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.1368 per EA under NDC 16252053901. Its NADAC has been published 150 times since Nov 28, 2013.
FDA first approved this application on Jan 5, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
16252053901
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ISRADIPINEApproval Type
Generic (ANDA)
FDA Application
ANDA077317FDA Approved
1/5/2006
TE Code
AB
On Market Since
1/5/2004
Pharmacological Classes
Price Statistics
The NADAC for ISRADIPINE 2.5 MG CAPSULE has been published 150 times since Nov 28, 2013, and over the history we have for it it has risen 21.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1368 per EA |
|---|---|
| All-time high | $1.8070 (Jan 14, 2026) |
| All-time low | $0.9249 (Sep 17, 2014) |
| 52-week high | $1.8070 |
| 52-week low | $1.1368 |
| Median price | $0.9587 |
| Average price | $1.1247 |
| Largest weekly change | +93.8% (Dec 17, 2025) |
| Weeks tracked | 150 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Isradipine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dihydropyridine Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ISRADIPINE 2.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ISRADIPINE 2.5 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $1.1368 per EA (NDC 16252053901), effective Sep 30, 2026.
How has the price of ISRADIPINE 2.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ISRADIPINE 2.5 MG CAPSULE has risen 21.6%. It has been tracked across 150 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ISRADIPINE 2.5 MG CAPSULE?
Since Nov 28, 2013, the NADAC for ISRADIPINE 2.5 MG CAPSULE has ranged from a low of $0.9249 (Sep 17, 2014) to a high of $1.8070 (Jan 14, 2026), with a median of $0.9587 per EA.
Are there cheaper alternatives to ISRADIPINE 2.5 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ISRADIPINE 2.5 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures ISRADIPINE 2.5 MG CAPSULE?
ISRADIPINE 2.5 MG CAPSULE (NDC 16252053901) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.